StockData
BioLineRx Ltd. logo

BioLineRx Ltd. (BLRX) shareholders

BLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 23, 2026Score 3/30
$1.12−0.03 (-2.61%)

Close on Nov 17, 2026Market cap $4.87MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
0.0%
0M of 2.61B shares
Institutional holders
14
4 new, 3 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Highbridge Capital Management, LLC172,950,6007.20%13G (passive)Jun 30, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of BLRXValueChange% of portfolio
Susquehanna International Group, Llp30,9110.00%$95.82KNew0.00%
Renaissance Technologies LLC15,4120.00%$48.09KNew0.00%
Citadel Advisors LLC14,7960.00%$45.87KNew0.00%
Rhumbline Advisers2,4780.00%$7.68K+1250.00%
Wells Fargo & Company/Mn2,0000.00%$6.24K+2500.00%
Bnp Paribas Arbitrage, Snc5000.00%$1.55K−1,3000.00%
Nemes Rush Group LLC2500.00%$780–0.00%
UBS Group AG1010.00%$315−4280.00%
NewEdge Advisors, LLC820.00%$256−250.00%
Osaic Holdings, Inc.260.00%$81–0.00%
SBI Securities Co., Ltd.100.00%$31New0.00%
Danske Bank A/S20.00%$6–0.00%
Citigroup Inc10.00%$3−1,7270.00%
Banque Cantonale Vaudoise10.00%$1.00M–0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026140M0.0%4 / 24 / 30M0M
Q1 2026130M0.0%1 / 13 / 20M0M
Q4 2025140M0.0%3 / 42 / 30M0M
Q3 2025140M0.0%3 / 13 / 60M0M
Q2 2025170M0.0%9 / 13 / 40M0M
Q1 2025120M0.0%12 / 00 / 10M0M
Q4 202410M0.0%1 / 00 / 00M0M

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Philip A. SerlinChief Executive Officer5,131,8000.20%Mar 27, 2026
Mali ZeeviChief Financial Officer1,311,0000.05%Mar 18, 2026
Shaoyu YanDirector––Apr 10, 2026
Sandra PanemDirector––Mar 31, 2026
Rami DarDirector––Mar 31, 2026
Avraham MolchoDirector––Mar 31, 2026
Raphael HofsteinDirector––Mar 31, 2026
Gal Avraham CohenDirector––Mar 30, 2026
Aharon SchwartzDirector3,705,0000.14%Mar 30, 2026
Barbara-Jean Anne Bormann-KennedyDirector––Mar 18, 2026

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
0M shares short
Days to cover
17.2
At 0M shares a day
Change since last report
-0.3%
From 0M shares
Short volume, 20 days
23.2%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of BioLineRx's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,862 shares on Oct 7, 2026 over the last 90 days.

See a number that looks wrong?